Cross-neutralization of #SARS-CoV-2 #BA322 #lineage by #JN1 #mRNA #vaccine-induced immunity

 

Highlights (for review)

    • JN.1 mRNA vaccination elicits cross-neutralizing antibodies against BA.3.2.2.

    • BA.3.2.2 is antigenically isolated from all circulating JN.1-descendant variants.

    • Retention of wild-type F456 in BA.3.2.2 preserves class 1/2 antibody epitopes.

    • AZD3152/sipavibart retains potent neutralization against BA.3.2.2.

    • VYD222/pemivibart maintains broad neutralization activity across all variants tested.

Abstract

The SARS-CoV-2 BA.3.2.2 sublineage has emerged globally as the dominant branch of BA.3.2 by late 2025, yet its antigenic relationship with JN.1 vaccine-induced immunity remains unclear. We evaluated neutralizing antibody responses in 25 JN.1 mRNA vaccinees against eight variants, stratified by anti-nucleocapsid antibody serostatus. Post-vaccination titers increased significantly against all variants in both N antibody-negative and -positive groups. Cross-neutralization against BA.3.2.2 was detected in both groups despite lower titers compared to JN.1. Antigenic cartography revealed that BA.3.2.2 was antigenically isolated from all JN.1-descendant variants. AZD3152/sipavibart retained potent neutralization against BA.3.2.2 but completely lost activity against all F456L-harboring JN.1-descendant variants, while VYD222/pemivibart and SA55 maintained broad activity. Retention of wild-type F456 in BA.3.2.2 preserves class 1/2 antibody epitopes, providing a mechanistic basis for cross-neutralization and suggesting a potential therapeutic window for sipavibart should BA.3.2.2 expand globally, pending clinical confirmation.

Source: 

Link: https://www.ijidonline.com/article/S1201-9712(26)00589-8/fulltext

____

#Coronavirus Disease Research #References (AMEDEO, July 5 '26)

 

Ann Intern Med

1. XIE Y, Choi T, Al-Aly Z
   Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00217.
   PubMed         Abstract available
   
   
2. 
   Summary for Patients: Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00217.
   PubMed        
   
   

   
   BMJ

3. COZZOLINO A
   Covid-19 vaccine study pulled by US CDC is finally published.
   BMJ. 2026;394:e100157.
   PubMed        
   
   

   
   J Infect

4. RAN J, Zhu L, Ning M, Zhang W, et al
   Age-associated impairment of humoral and cellular immune responses to SARS-CoV-2 in a large community cohort with hybrid immunity.
   J Infect. 2026 Jul 1:106803. doi: 10.1016/j.jinf.2026.106803.
   PubMed         Abstract available
   
   

   
   J Med Virol

5. WIDANAGAMAACHCHI WN, Callahan AR, Willson TM, Barbeau B, et al
   How Many Veteran COVID-19 Cases Were There during the Pandemic?
   J Med Virol. 2026;98:e71040.
   PubMed         Abstract available
   
   

   
   J Travel Med

6. KASSIANOS G, Goodyer L, Gomensoro EEB, Doobaree U, et al
   Assessment of the healthcare burden of dengue disease in England: a retrospective analysis (2010-2023).
   J Travel Med. 2026 Jul 2:taag059. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

7. ZHOU X, Ivanov KI, Ge X, Guo X, et al
   Identification of GRP78 as a novel host factor that facilitates zoonotic porcine deltacoronavirus internalization and replication via clathrin-mediated endocytosis.
   J Virol. 2026 Jul 2:e0071726. doi: 10.1128/jvi.00717.
   PubMed         Abstract available
   
   
8. TIWAREKAR V, Ebenig A, Predota Y, Schrauf S, et al
   Minor differences in the untranslated regions of measles vector additional transcription units are reflected by differential immunogenicity of encoded MERS-CoV Spike antigen.
   J Virol. 2026 Jul 1:e0064426. doi: 10.1128/jvi.00644.
   PubMed         Abstract available
   
   
9. ZHANG L, Li Y, Zhao J, Liang R, et al
   Characterization of nucleolar localization signals in the avian infectious bronchitis virus nucleocapsid protein and their critical role in viral replication.
   J Virol. 2026;100:e0043326.
   PubMed         Abstract available
   
   

   
   JAMA

10. LEUNG PB, Davis AM, Marks KM
    Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection.
    JAMA. 2026 Jun 30. doi: 10.1001/jama.2026.6918.
    PubMed        
    
    

    
    Lancet

11. BLAKNEY AK, Top KA, Cowling BJ, Larson HJ, et al
    Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.
    Lancet. 2026 Jun 30:S0140-6736(26)00512-X. doi: 10.1016/S0140-6736(26)00512.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, July 5 '26)

 

Ann Intern Med

1. 
   Summary for Patients: Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00217.
   PubMed        
   
   
2. XIE Y, Choi T, Al-Aly Z
   Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00217.
   PubMed         Abstract available
   
   

   
   Antiviral Res

3. YANG X, Wu L, Wan G, Chen R, et al
   The anti-respiratory syncytial virus activity of biochemicals from Pyrola incarnata.
   Antiviral Res. 2026;252:106473.
   PubMed         Abstract available
   
   

   
   Arch Virol

4. ALVES MCS, Falcao RM, de Jesus Palmeira OF, de Sa Leitao Paiva-Junior S, et al
   Genomic and epidemiological characterization of SARS-CoV-2 in Northeastern Brazil: a comprehensive analysis (2020-2024).
   Arch Virol. 2025;171:1.
   PubMed         Abstract available
   
   
5. NEHUL S, Nagaraj SK, Narayan R, Singh A, et al
   A novel molecule inhibits SARS-CoV-2 RBD binding to the ACE2 receptor, blocks viral entry and exhibits antiviral activity in a murine model.
   Arch Virol. 2026;171:98.
   PubMed         Abstract available
   
   
6. MOYUE X, Liang S, Ying X, Yang Y, et al
   Research progress of nucleocapsid protein of novel coronavirus: structure, function and targeted therapy.
   Arch Virol. 2026;171:120.
   PubMed         Abstract available
   
   
7. CHEPURNOV A, Miroshnichenko S, Ivanov M, Solomatina M, et al
   Specific features of the infection caused by SARS-CoV-2 variants in Vero cell culture.
   Arch Virol. 2026;171:133.
   PubMed         Abstract available
   
   
8. JONES LR, D'Andrea JS, Levite J, Brito M, et al
   Viral genotype and the pace of epidemic waves: an assessment from SARS-CoV 2 genomics and wastewater surveillance data.
   Arch Virol. 2026;171:163.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

9. ASAFO-AGYEI SB, Ameyaw E, Nguah SB, Paintsil V, et al
   Immunisation status and clinical outcomes in children admitted to a Paediatric emergency unit in Ghana: a prospective cohort study.
   BMC Pediatr. 2025;25:981.
   PubMed         Abstract available
   
   
10. PU F, Hao YQ
    Impact of COVID-19 epidemic prevention and control measures on the incidence of asthma in children.
    BMC Pediatr. 2026;26:8.
    PubMed         Abstract available
    
    
11. AVSAR H, Bulbul A, Bas EK, Uslu HS, et al
    Maternal-infant vitamin D coupling and neonatal hypocalcemia: a six-year cohort integrating preterm risk, onset timing, and pandemic effects.
    BMC Pediatr. 2026 Jan 27. doi: 10.1186/s12887-026-06532.
    PubMed        
    
    
12. MOHAMMADI R, Barzegar H, Zamani Z, Gorji M, et al
    Hospitalization outcomes and laboratory correlations in pediatric MIS-C patients: a retrospective cross-sectional study in Tehran, Iran.
    BMC Pediatr. 2026;26:205.
    PubMed         Abstract available
    
    
13. MIYAGI Y, Morimoto Y, Satake E, Iwashima S, et al
    Identification of key clinical features for pediatric respiratory syncytial virus infection using machine learning.
    BMC Pediatr. 2026;26:266.
    PubMed         Abstract available
    
    
14. COBAN Y, Evren G, Yildizdas D, Zengin N, et al
    Burden, risk factors, and outcomes respiratory syncytial virus (RSV) infection in pediatric intensive care units in Turkiye (RSVP Study 2020-2024).
    BMC Pediatr. 2026 Mar 5. doi: 10.1186/s12887-026-06562.
    PubMed        
    
    
15. AKALIN H, Kilic A, Ozcetin M, Yildiz I, et al
    The effect of Covid 19 pandemic on childhood obesity in Turkey.
    BMC Pediatr. 2026;26:310.
    PubMed         Abstract available
    
    
16. SCHMIDT L, Feddern S, Kossow A, Niessen J, et al
    Severe acute COVID-19 and early long COVID signals in paediatric cohorts: an analysis of real-world data from two health departments, Germany.
    BMC Pediatr. 2026;26:280.
    PubMed         Abstract available
    
    
17. HANSEN G, Holt T
    RSV bronchiolitis versus COVID-19: could pediatric intensive care units have done more during the pandemic?
    BMC Pediatr. 2026 Apr 11. doi: 10.1186/s12887-026-06850.
    PubMed        
    
    

    
    J Gen Virol

18. KUOK DIT, Ma APY, Ching RHH, Ng KC, et al
    Assessment of influenza virus and coronavirus tropism, replication competence and disease severity in ex vivo and in vitro cultures of the human respiratory tract.
    J Gen Virol. 2026;107:002281.
    PubMed         Abstract available
    
    

    
    J Virol

19. LI P, Zheng Y-M, Liu S-L
    Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants.
    J Virol. 2026 May 12:e0001626. doi: 10.1128/jvi.00016.
    PubMed         Abstract available
    
    
20. MCCABE M, Groves HE, Getty E, Campbell E, et al
    Age-dependent expression and antiviral activity of interferon epsilon in respiratory epithelium.
    J Virol. 2026 May 12:e0057825. doi: 10.1128/jvi.00578.
    PubMed         Abstract available
    
    
21. SIVARAJAN R, Kirchgatterer PC, Lawrenz J, Tanner-Matiz E, et al
    Tonic and early interferons defend against respiratory viruses in primary human lung organoid-derived air-liquid interface cultures.
    J Virol. 2026 May 20:e0210425. doi: 10.1128/jvi.02104.
    PubMed         Abstract available
    
    
22. FAN L, Gao X, Feng W, Huang Q, et al
    SARS-CoV-2 ORF3a suppresses host antiviral interferon responses by promoting STUB1-mediated PTEN proteasomal degradation.
    J Virol. 2026 Jun 2:e0018626. doi: 10.1128/jvi.00186.
    PubMed         Abstract available
    
    
23. SUSMA B, Spronken M, van Nieuwkoop S, Kalverda B, et al
    Increased or decreased numbers of CpG dinucleotide motifs in the genome of influenza A virus do not affect in vitro virus phenotype.
    J Virol. 2026 Jun 22:e0004726. doi: 10.1128/jvi.00047.
    PubMed         Abstract available
    
    
24. ZHANG Q, Zhang Y, Sun H, Li H, et al
    Single-cell and spatial transcriptomic profiling reveals distinct immune landscapes in murine lungs infected with H1N1 versus H5N1 influenza viruses.
    J Virol. 2026 Jun 29:e0074626. doi: 10.1128/jvi.00746.
    PubMed         Abstract available
    
    
25. KATO K, Okamura K, Nakamura Y, Iwata M, et al
    Influenza A virus infection induces initial proliferation of commensal Streptococcus pneumoniae in the larynx leading to dissemination into the lower respiratory tract.
    J Virol. 2026 Jun 29:e0055526. doi: 10.1128/jvi.00555.
    PubMed         Abstract available
    
    

    
    Pediatrics

26. GERHART J, Leister-Tebbe H, Chan PLS, McComsey GA, et al
    Nirmatrelvir/Ritonavir for the Treatment of COVID-19 in Children Aged 6 Years and Older.
    Pediatrics. 2026 Jun 25:e2025073999. doi: 10.1542/peds.2025-073999.
    PubMed         Abstract available
    
    
27. ZMUDA E, Hannon TS, Valentic J
    The Role of the Pediatrician to Promote Effective Approaches for Child and Adolescent Nutrition in Schools: Policy Statement.
    Pediatrics. 2026 Jun 15:e2026077404. doi: 10.1542/peds.2026-077404.
    PubMed         Abstract available
    
    
28. MEHROTRA-VARMA S, Nguyen HQ, Henry S, Collins J, et al
    Long-Term Outcomes of Multisystem Inflammatory Syndrome in Children up to 4.5 Years After COVID-19.
    Pediatrics. 2026;158:e2025075578.
    PubMed         Abstract available
    
    

    
    PLoS One

29. HUANG L, Wang TM, Sugimoto JD, Heberer KR, et al
    Association of SARS-CoV-2 infection with incident diabetes among U.S. Veterans in a prospective longitudinal cohort.
    PLoS One. 2026;21:e0351992.
    PubMed         Abstract available
    
    
30. ALLARDET-SERVENT J, Hezard N, Pissier C, Bardin N, et al
    Circulating biomarkers of bronchoalveolar injury help predict the need for mechanical ventilation in patients with moderate to severe COVID-19 pneumonia: A prospective cohort study.
    PLoS One. 2026;21:e0337792.
    PubMed         Abstract available
    
    
31. NAZIR A, Shorfuzzaman M, Lotfi ML, Kamalov F, et al
    Forecasting COVID-19 new cases using NBEATS deep learning and mobility data.
    PLoS One. 2026;21:e0350264.
    PubMed         Abstract available
    
    
32. WERTZ E, Babinska M, Batorski D, Louison-Lavoy D, et al
    Ad-based social media interventions increase belief accuracy and generate pro-social opinions among non-news readers.
    PLoS One. 2026;21:e0352588.
    PubMed         Abstract available
    
    
33. HERNANDEZ-ORTIZ BA, Dos Santos TA, Appolinario CM, Arcila-Cardona AM, et al
    Spatial association of seabirds and aquatic birds with highly pathogenic avian influenza (H5N1) outbreaks in Brazil: A nationwide ecological and statistical modelling approach.
    PLoS One. 2026;21:e0350505.
    PubMed         Abstract available
    
    
34. KEARNEY GD, Obi ON, Maddipati V, Levitin G, et al
    Social vulnerability and spatial patterns of COVID-19 mortality: Global implications for respiratory health equity.
    PLoS One. 2026;21:e0352270.
    PubMed         Abstract available
    
    
35. KATUSIIME L, Agbola FW
    Determinants of mobile money loan disbursements: Evidence from Uganda's post pandemic digital credit boom.
    PLoS One. 2026;21:e0338535.
    PubMed         Abstract available
    
    
36. KIERNAN EA, Guzman JD
    Paying in public: Peer effects, impression management, and willingness to pay on digital payment platforms.
    PLoS One. 2026;21:e0340550.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

37. CAO J, Liu S, Su C, Wang L, et al
    Genomic and structural evidence of SARS-CoV-2 and MERS-CoV in migratory birds.
    Proc Natl Acad Sci U S A. 2026;123:e2400023123.
    PubMed         Abstract available
    
    
38. METZGER SM, Jones TC, Meier JIJ, Richter A, et al
    Evaluation of a proposed link between the SARS-CoV-2 furin cleavage site and mouse-adapted MERS-coronavirus MA30.
    Proc Natl Acad Sci U S A. 2026;123:e2601806123.
    PubMed         Abstract available
    
    
39. TYLLIS TS, Norton TS, Abbott C, McPeake DJ, et al
    B cell-intrinsic CXCR3 drives efficient generation of ectopic pulmonary germinal center responses to influenza A virus infection.
    Proc Natl Acad Sci U S A. 2026;123:e2535787123.
    PubMed         Abstract available
    
    
40. SOEWONGSONO AC, Thompson A, Landis MJ
    Inferring epidemiological parameters under an infectious phylogeography model with visitor dynamics.
    Proc Natl Acad Sci U S A. 2026;123:e2535042123.
    PubMed         Abstract available
    
    

    
    Vaccine

41. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Corrigendum to "Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial" [Vaccine 42(9) (2024) 2254-2259].
    Vaccine. 2026;88:128881.
    PubMed        
    
    
42. BARBAROUX A, Serati I, Milhabet I
    Effectiveness and acceptability of an opt-out nudge to promote influenza vaccination among medical residents: A randomized controlled trial.
    Vaccine. 2026;89:128894.
    PubMed         Abstract available
    
    
43. MORRIS SE, O'Halloran A, Sundaresan D, Olson SM, et al
    Public health benefits of maternal influenza vaccination among pregnant women and infants <6 months in the United States, 2011-2020.
    Vaccine. 2026;89:128895.
    PubMed         Abstract available
    
    
44. HALWE NJ, Krammer F
    Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.
    Vaccine. 2026;89:128877.
    PubMed         Abstract available